Tag: Jak stat pathway

Myelofibrosis is a complex bone marrow cancer characterized by overactive Janus kinase (JAK) signaling, which leads to the formation of scar tissue. Jakafi is a targeted therapy designed to address this underlying mechanism by inhibiting key JAK proteins.

Discovered in the early 1990s, Janus kinases, or JAKs, are a family of intracellular non-receptor tyrosine kinases that play a critical role in cellular signaling. Understanding **what is a janus kinase?** is key to comprehending the fundamental JAK-STAT signaling pathway, which controls a vast range of cellular activities, from immune responses to cell growth.